SSG
RYTM icon

Summit Securities Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

Summit Securities Group’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,500
Closed -$34K – 870
2023
Q3 		$34K Buy
+1,500
New +$33.6K ﹤0.01% 322

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Summit Securities Group's RYTM Position: Q2 2026 in Review

Summit Securities Group opened a new position in Rhythm Pharmaceuticals (RYTM) in Q2 2026: 543 shares worth $60.3K. The stake represents 0.01% of the portfolio and ranks #548 among its holdings.

304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Summit Securities Group held 543 shares of Rhythm Pharmaceuticals worth $60.3K as of Q2 2026.
  • Rhythm Pharmaceuticals was a new Summit Securities Group position in Q2 2026.
  • Rhythm Pharmaceuticals made up 0.01% of Summit Securities Group's portfolio in Q2 2026, its #548 holding.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.